BRPI0816345A2 - Formas sólidas de n-[2,4-bis-(1,1-dimetiletil)-5-hidroxifenil]-1,4-diidro-4-o xoquinolin-3-carboxamida - Google Patents

Formas sólidas de n-[2,4-bis-(1,1-dimetiletil)-5-hidroxifenil]-1,4-diidro-4-o xoquinolin-3-carboxamida

Info

Publication number: BRPI0816345A2
Authority: BR; Brazil
Prior art keywords: xoquinolin; diidro; dimethylethyl; carboxamide; hydroxyphenyl
Prior art date: 2007-09-14

Application number

BRPI0816345-6A2A

Other languages

English (en)

Inventor

John Demattei

Yushi Feng

Cristian Harrison

Adam Looker

Praveen Mudunuri

Stefanie Roeper

Yuegang Zhang

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-14

Filing date

2008-09-15

Publication date

2015-02-24

2008-09-15 Application filed by Vertex Pharma filed Critical Vertex Pharma

2015-02-24 Publication of BRPI0816345A2 publication Critical patent/BRPI0816345A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Neurology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Epidemiology (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

BRPI0816345-6A2A 2007-09-14 2008-09-15 Formas sólidas de n-[2,4-bis-(1,1-dimetiletil)-5-hidroxifenil]-1,4-diidro-4-o xoquinolin-3-carboxamida BRPI0816345A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US97260507P	2007-09-14	2007-09-14
PCT/US2008/010728 WO2009038683A2 (en)	2007-09-14	2008-09-15	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Publications (1)

Publication Number	Publication Date
BRPI0816345A2 true BRPI0816345A2 (pt)	2015-02-24

Family

ID=40468681

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0816345-6A2A BRPI0816345A2 (pt)	2007-09-14	2008-09-15	Formas sólidas de n-[2,4-bis-(1,1-dimetiletil)-5-hidroxifenil]-1,4-diidro-4-o xoquinolin-3-carboxamida

Country Status (11)

Country	Link
US (3)	US8163772B2 (pt)
EP (1)	EP2222304A2 (pt)
JP (1)	JP2010540417A (pt)
CN (1)	CN101918366A (pt)
AU (1)	AU2008301907B2 (pt)
BR (1)	BRPI0816345A2 (pt)
CA (1)	CA2699292A1 (pt)
MX (1)	MX2010002974A (pt)
NZ (3)	NZ600865A (pt)
RU (1)	RU2010114732A (pt)
WO (1)	WO2009038683A2 (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
ZA200602755B (en)	2003-09-06	2007-06-27	Vertex Pharma	Modulators of ATP-binding cassette transporters
CN101675928A (zh) *	2003-11-14	2010-03-24	沃泰克斯药物股份有限公司	可用作atp-结合***转运蛋白调控剂的噻唑和噁唑
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
RS53895B1 (en) *	2004-06-24	2015-08-31	Vertex Pharmaceuticals Incorporated	ATP-BINDING CASSETTE TRANSPORT MODULATORS
EP1912983B1 (en)	2005-08-11	2011-06-08	Vertex Pharmaceuticals, Inc.	Modulators of cystic fibrosis transmembrane conductance regulator
PT1945632E (pt)	2005-11-08	2013-12-24	Vertex Pharma	Moduladores heterocíclicos de transportadores de cassete de ligação a atp
US7671221B2 (en) *	2005-12-28	2010-03-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
PL3219705T3 (pl)	2005-12-28	2020-08-10	Vertex Pharmaceuticals Incorporated	Kompozycje farmaceutyczne amorficznych postaci n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4-dihydro-4-oksochinolino-3-karboksyamidu
US7691902B2 (en)	2005-12-28	2010-04-06	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
ES2882684T3 (es)	2006-04-07	2021-12-02	Vertex Pharma	Preparación de moduladores de transportadores del casete de unión a ATP
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
US8969386B2 (en)	2007-05-09	2015-03-03	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
WO2009038913A2 (en)	2007-08-24	2009-03-26	Vertex Pharmaceuticals Incorporated	Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
CN101918366A (zh) *	2007-09-14	2010-12-15	弗特克斯药品有限公司	N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的固体形式
NZ598941A (en)	2007-11-16	2013-06-28	Vertex Pharma	Isoquinoline modulators of ATP-Binding Cassette transporters
US20100036130A1 (en) *	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
DK3170818T3 (da)	2007-12-07	2020-04-14	Vertex Pharma	Faste former af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
SI2639224T1 (sl)	2007-12-07	2016-12-30	Vertex Pharmaceuticals Incorporated	Postopek za pripravo cikloalkilkarboksiamido-piridinskih benzojskih kislin
AU2008335439A1 (en) *	2007-12-07	2009-06-18	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
NZ602030A (en)	2008-02-28	2014-02-28	Vertex Pharma	Heteroaryl derivatives as cftr modulators
EP2980077B1 (en) *	2008-03-31	2020-05-06	Vertex Pharmaceuticals Incorporated	Pyridyl derivatives as cftr modulators
AR073709A1 (es) *	2008-09-29	2010-11-24	Vertex Pharma	Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico
SI2349263T1 (sl) *	2008-10-23	2014-09-30	Vertex Pharmaceuticals Incorporated	Modulatorji cistiäśno-fibroznega transmembranskega regulatorja prevodnosti
SI2821400T1 (en)	2009-03-20	2018-02-28	Vertex Pharmaceuticals Incorporated	A process for the manufacture of a transmembrane conductivity regulator in cystic fibrosis
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
DK3150198T3 (da)	2010-04-07	2021-11-01	Vertex Pharma	Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
RS54783B1 (sr)	2010-04-07	2016-10-31	Vertex Pharma	Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzoeve kiseline
EP2560649A1 (en)	2010-04-22	2013-02-27	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
EP2560650A1 (en) *	2010-04-22	2013-02-27	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
CN105130948A (zh)	2010-04-22	2015-12-09	弗特克斯药品有限公司	制备环烷基甲酰胺基-吲哚化合物的方法
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
HUE047354T2 (hu)	2011-05-18	2020-04-28	Vertex Pharmaceuticals Europe Ltd	Ivacaftor deuterizált származékai
US9254291B2 (en)	2011-11-08	2016-02-09	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
EP2819670A1 (en)	2012-02-27	2015-01-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administration thereof
US8674108B2 (en)	2012-04-20	2014-03-18	Vertex Pharmaceuticals Incorporated	Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CA2869847A1 (en) *	2012-04-20	2013-10-24	Vertex Pharmaceuticals Incorporated	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CA2878057A1 (en)	2012-07-16	2014-01-23	Rossitza Gueorguieva Alargova	Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
LT2914248T (lt) *	2012-11-02	2018-11-26	Vertex Pharmaceuticals Incorporated	Farmacinės kompozicijos, skirtos cftr medijuotų ligų gydymui
EP2951158B1 (en) *	2013-01-31	2019-05-29	Glenmark Pharmaceuticals Limited	Process for the preparation of ivacaftor and solvates thereof
WO2014125506A2 (en)	2013-02-15	2014-08-21	Laurus Labs Private Limited	A process for the preparation of ivacaftor and its intermediates
HUE054389T2 (hu)	2013-11-12	2021-09-28	Vertex Pharma	Eljárás CFTR-mediálta betegségek kezelésére szolgáló gyógyászati kompozíciók elõállítására
CA2927661A1 (en) *	2013-11-13	2015-05-21	Apotex Inc.	Solid forms of ivacaftor and processes for the preparation thereof
WO2015128882A2 (en) *	2014-02-27	2015-09-03	Msn Laboratories Private Limited	Crystalline forms of n-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide and process for the preparation thereof
RS57476B9 (sr)	2014-04-15	2021-10-29	Vertex Pharma	Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
GB201415381D0 (en)	2014-08-29	2014-10-15	Algipharma As	Inhalable powder formulations of alginate oligomers
WO2016057572A1 (en)	2014-10-06	2016-04-14	Mark Thomas Miller	Modulators of cystic fibrosis transmembrane conductance regulator
JP6746569B2 (ja) *	2014-10-07	2020-08-26	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶
ES2882656T3 (es)	2014-11-18	2021-12-02	Vertex Pharma	Proceso para realizar pruebas de alto rendimiento de cromatografía líquida de alta resolución
GB201504878D0 (en)	2015-03-23	2015-05-06	Algipharma As	Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
CA2999529A1 (en)	2015-09-25	2017-03-30	Vertex Pharmaceuticals (Europe) Limited	Deuterated cftr potentiators
GB201517639D0 (en)	2015-10-06	2015-11-18	Algipharma As	Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
GEP20217329B (en)	2016-09-30	2021-12-10	Vertex Pharma	Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EA202192783A1 (ru)	2016-12-09	2022-02-24	Вертекс Фармасьютикалз Инкорпорейтед	Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
AU2018279646B2 (en)	2017-06-08	2023-04-06	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
CA3069226A1 (en)	2017-07-17	2019-01-24	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
MX2020001302A (es)	2017-08-02	2020-03-20	Vertex Pharma	Procesos para preparar compuestos de pirrolidina.
TWI719349B (zh)	2017-10-19	2021-02-21	美商維泰克斯製藥公司	Ｃｆｔｒ調節劑之結晶形式及組合物
CA3082444A1 (en)	2017-12-01	2019-06-06	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
CA3085006A1 (en)	2017-12-08	2019-06-13	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
SI3752510T1 (sl)	2018-02-15	2023-03-31	Vertex Pharmaceuticals Incorporated	Makrocikli kot modulatorji regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki iz le-teh, njihova uporaba pri zdravljenju cistične fibroze in postopek za njihovo proizvodnjo
EP3774825A1 (en)	2018-04-13	2021-02-17	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN114599657A (zh)	2019-08-14	2022-06-07	弗特克斯药品有限公司	Cftr调节剂的结晶形式
TW202115092A (zh)	2019-08-14	2021-04-16	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白之調節劑
TW202120517A (zh)	2019-08-14	2021-06-01	美商維泰克斯製藥公司	製備cftr調節劑之方法
US11384054B2 (en)	2020-10-22	2022-07-12	Scinopharm Taiwan, Ltd.	Crystalline form of ivacaftor and a process for preparing the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100074949A1 (en) *	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
SE0201669D0 (sv) *	2002-06-03	2002-06-03	Pharmacia Ab	New formulation and use thereof
RS53895B1 (en) *	2004-06-24	2015-08-31	Vertex Pharmaceuticals Incorporated	ATP-BINDING CASSETTE TRANSPORT MODULATORS
PL3219705T3 (pl) *	2005-12-28	2020-08-10	Vertex Pharmaceuticals Incorporated	Kompozycje farmaceutyczne amorficznych postaci n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4-dihydro-4-oksochinolino-3-karboksyamidu
CN101918366A (zh) *	2007-09-14	2010-12-15	弗特克斯药品有限公司	N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的固体形式
US20100256184A1 (en) *	2008-08-13	2010-10-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
SI2821400T1 (en) *	2009-03-20	2018-02-28	Vertex Pharmaceuticals Incorporated	A process for the manufacture of a transmembrane conductivity regulator in cystic fibrosis

2008
- 2008-09-15 CN CN200880116588XA patent/CN101918366A/zh active Pending
- 2008-09-15 NZ NZ600865A patent/NZ600865A/en not_active IP Right Cessation
- 2008-09-15 CA CA2699292A patent/CA2699292A1/en not_active Abandoned
- 2008-09-15 BR BRPI0816345-6A2A patent/BRPI0816345A2/pt not_active IP Right Cessation
- 2008-09-15 NZ NZ583848A patent/NZ583848A/en not_active IP Right Cessation
- 2008-09-15 WO PCT/US2008/010728 patent/WO2009038683A2/en active Application Filing
- 2008-09-15 MX MX2010002974A patent/MX2010002974A/es unknown
- 2008-09-15 AU AU2008301907A patent/AU2008301907B2/en not_active Ceased
- 2008-09-15 JP JP2010524884A patent/JP2010540417A/ja active Pending
- 2008-09-15 RU RU2010114732/04A patent/RU2010114732A/ru not_active Application Discontinuation
- 2008-09-15 NZ NZ620027A patent/NZ620027A/en not_active IP Right Cessation
- 2008-09-15 US US12/283,702 patent/US8163772B2/en active Active
- 2008-09-15 EP EP08832069A patent/EP2222304A2/en not_active Withdrawn
2012
- 2012-03-06 US US13/413,327 patent/US8362253B2/en active Active
- 2012-12-14 US US13/714,911 patent/US8623894B2/en active Active

Also Published As

Publication number	Publication date
US8362253B2 (en)	2013-01-29
CN101918366A (zh)	2010-12-15
US8623894B2 (en)	2014-01-07
US20090099230A1 (en)	2009-04-16
EP2222304A2 (en)	2010-09-01
WO2009038683A3 (en)	2010-08-26
JP2010540417A (ja)	2010-12-24
NZ620027A (en)	2015-05-29
NZ583848A (en)	2012-07-27
MX2010002974A (es)	2010-07-29
WO2009038683A2 (en)	2009-03-26
NZ600865A (en)	2014-01-31
RU2010114732A (ru)	2011-10-20
US20120165372A1 (en)	2012-06-28
CA2699292A1 (en)	2009-03-26
AU2008301907B2 (en)	2014-02-20
AU2008301907A1 (en)	2009-03-26
US20130109717A1 (en)	2013-05-02
US8163772B2 (en)	2012-04-24

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.
2016-03-29	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0816345A2 (pt)	2015-02-24	Formas sólidas de n-[2,4-bis-(1,1-dimetiletil)-5-hidroxifenil]-1,4-diidro-4-o xoquinolin-3-carboxamida
PT1993360T (pt)	2017-05-25	Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida
IL244442A0 (en)	2016-04-21	Compounds of converted acylanilides and their use
CR20130381A (es)	2013-09-12	Formas farmacéuticas con propiedades farmacocinéticas mejoradas
BRPI0909084A2 (pt)	2015-08-11	Composição líquida, e, composto de peptídeo.
BRPI0920082A2 (pt)	2019-09-24	forma de dosagem oral de acetaminofeno/tramadol com liberação estendida.
SMP200900085B (it)	2010-11-12	3-imidazolil-indoli per il trattamento di malattieproliferative.
BRPI0818572A2 (pt)	2015-04-22	Depósito de material, e, dispositivo elétrico
BRPI0818373A2 (pt)	2017-05-16	compostos de pelicetal, síntese e aplicações
DK2010159T3 (da)	2012-10-22	Paracetamoltabletter med hurtig frigivelse
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
BRPI0807220B1 (pt)	2016-11-16	composição, e, métodos para aumentar a força de compressão de uma composição e para aumentar a retenção de fragrância de uma composição
BRPI0815578A2 (pt)	2015-02-18	Peptídeo de cdca1 e agente farmacêutico compreendendo o mesmo.
BRPI0818408A2 (pt)	2015-09-15	processos para preparar diamidas sulfúricas e ingredientes herbricidas atvos.
IL200514A0 (en)	2010-04-29	Solid forms comprising (-) o-desmethylvenlafaxine and uses thereof
BRPI0812015A2 (pt)	2014-11-18	Membro de reforço de borracha e produto de borracha utilizando o mesmo.
ATE500217T1 (de)	2011-03-15	Fluorhaltige organoschwefelverbindung und pestizidzusammensetzung, die diese enthält
BRPI0911578A2 (pt)	2017-06-20	ensaio de acetaminofeno.
BRPI0911772A2 (pt)	2017-06-27	composto, composição farmacêutica, e, uso do composto.
DK1896399T3 (da)	2011-02-21	Biphenyl- og naphthylphenyl-hydroxamsyre-derivater
CR10685A (es)	2009-05-22	Proceso para estabilizaciuon de famotidina
BR112012002311A2 (pt)	2016-05-31	composto, composição farmacêutica, e, uso do composto.
BRPI0810776A2 (pt)	2014-10-07	Uso de uma dispersão aquosa, dispersão aquosa, e, composição cosmética.
DE502006000922D1 (de)	2008-07-24	Richtung
BRPI0808927A2 (pt)	2014-10-07	Formas sólidas de microbiocida